Our Science
Overcoming the challenges of drugging intracellular targets
Vesigen’s therapeutic programs employ engineered ARMMs to deliver RNA, proteins, and gene-editing complexes to cells that are not otherwise accessible. Unlike existing delivery systems, which are limited by toxicity, immunogenicity, poor cell/tissue specificity, and reduced cellular activity due to endosomal trapping or endolysosomal processing, ARMMs technology overcomes these limitation to achieve safe and efficient functional delivery of therapeutic molecules.